SAMSUNG PHARMACEUTICAL Co., Ltd.
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 89
- Market Cap
- -
- Website
- http://www.sspharm.co.kr
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)β’ Click on a phase to view related trials
Phase 3
2 (100.0%)GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
Phase 3
Not yet recruiting
- Conditions
- Moderate to Severe Alzheimer's Disease
- Interventions
- Drug: GV1001 PlaceboDrug: GV1001 1.12mg
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Samsung Pharmaceutical Co., Ltd.
- Target Recruit Count
- 750
- Registration Number
- NCT05303701
A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Samsung Pharmaceutical Co., Ltd.
- Target Recruit Count
- 148
- Registration Number
- NCT02854072
- Locations
- π°π·
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
π°π·Wonju Severance Christian Hospital, Wonju-si, Gangwon-do, Korea, Republic of
π°π·National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
News
No news found